Publications
| 2008-03-05 |
Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections, Clinical and Vaccine Immunology, March 2008 |
| US Army Medical Research Institute of Infectious Diseases (USAMRIID) publishes the success of the first multivalent Ebola and Marburg virus (pan-filo) vaccine developed with GenPhar, Inc. |
| Published in the March 2008 edition of Clinical and Vaccine Immunology (http://cvi.asm.org) Use the link below to view the article abstract at the journal's website Link to Abstract |
| About GenPhar, Inc. GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world’s most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina. To learn more about GenPhar and its vaccine programs, please contact us. |


print this page
site map